Figure 3
From: Clinicopathological values of PD-L1 expression in HER2-positive breast cancer
(a) Cumulative survival of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer stratified according to programmed death-ligand 1 (PD-L1) expression. PD-L1 was not a significant prognostic factor in HER2-positive breast cancer. (b) Survival curves stratified according to the degrees of CD8-positive tumor-infiltrating lymphocytes (TILs) in PD-L1-negative/HER2-positive patients. Among PD-L1-negative/HER2-positive patients, recurrence-free survival was significantly better in the high CD8-positive TILs group than in the low CD8-positive TILs group.
